University of Pennsylvania

Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

Tmunity Therapeutics, Inc. is a bio-therapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, the company specializes in harnessing the potential of T cells through the creation of novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. These products are designed to provide superior control over T cell activation and direction in vivo. Tmunity employs proprietary technologies for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The company's expert founding team has extensive experience in T-cell biology, manufacturing, regulatory affairs, and clinical development, enabling them to efficiently advance personalized next-generation immunotherapies into clinical trials. Tmunity's robust manufacturing platform has demonstrated success in supporting multi-center clinical studies across a variety of therapeutic areas.

Behavior Change for Good Initiative is solving the mystery of enduring behavior change offers an enormous opportunity to improve lives.

Avisi Technologies Inc. is focused on developing innovative solutions to combat glaucoma, a leading cause of irreversible blindness. The company has created VisiPlate, a next-generation aqueous shunt designed for mid to late-stage glaucoma treatment. This product is notable for its ultrathin design, being 20 times thinner than a human hair, which facilitates a less invasive insertion procedure that reduces operating time and simplifies follow-up care. VisiPlate is constructed from alumina, a material recognized for its use in hip replacements, thus ensuring biocompatibility. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Avisi Technologies aims to address the challenges associated with current glaucoma treatments, including patient non-compliance and post-operative complications, ultimately striving to prevent blindness in affected individuals.

Tmunity Therapeutics, Inc. is a bio-therapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, the company specializes in harnessing the potential of T cells through the creation of novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. These products are designed to provide superior control over T cell activation and direction in vivo. Tmunity employs proprietary technologies for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The company's expert founding team has extensive experience in T-cell biology, manufacturing, regulatory affairs, and clinical development, enabling them to efficiently advance personalized next-generation immunotherapies into clinical trials. Tmunity's robust manufacturing platform has demonstrated success in supporting multi-center clinical studies across a variety of therapeutic areas.

Tmunity Therapeutics, Inc. is a bio-therapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, the company specializes in harnessing the potential of T cells through the creation of novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. These products are designed to provide superior control over T cell activation and direction in vivo. Tmunity employs proprietary technologies for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The company's expert founding team has extensive experience in T-cell biology, manufacturing, regulatory affairs, and clinical development, enabling them to efficiently advance personalized next-generation immunotherapies into clinical trials. Tmunity's robust manufacturing platform has demonstrated success in supporting multi-center clinical studies across a variety of therapeutic areas.

Grand Round Table Inc. is a developer of clinical decision support tools aimed at enhancing diagnostic accuracy for healthcare providers. The company's flagship system, Grand Round Table, integrates with electronic health records to assist doctors in diagnosing patients by comparing their cases against a comprehensive database of deidentified health records, case reports, and evidence-based medical literature, including resources from the University of Pennsylvania. This technology enables physicians to access insights from previous cases, facilitating quicker and more informed treatment decisions for complex patients. By streamlining the decision-making process, Grand Round Table helps hospitals and clinics reduce unnecessary tests, ineffective treatments, and consultations, ultimately saving time and costs in patient care. Established in 2011, the company is headquartered in Philadelphia, Pennsylvania.